On September 5, 2026, clinical oncology panels reaffirmed Enhertu® (Trastuzumab deruxtecan 100 mg powder for concentrate for solution for infusion) developed by Daiichi Sankyo and AstraZeneca as a paradigm-shifting antibody-drug conjugate (ADC) transforming metastatic cancer care. Delivering extraordinary therapeutic benefit across HER2-positive and previously untargeted HER2-low metastatic breast cancer, HER2-mutant non-small cell lung cancer (NSCLC), and advanced gastric adenocarcinoma, Enhertu represents the new apex of precision oncology.

Through Critical Kare Pharma, certified authentic manufacturer packs of Enhertu Trastuzumab Deruxtecan 100mg Injection are accessible to oncology institutions, clinical research centers, and named patients globally via GDP-certified 2°C–8°C cold-chain logistics and validated Certificate of Analysis (COA) batch release.

Next-Generation ADC Engineering & Bystander Killing

Enhertu is an antibody-drug conjugate engineered with novel pharmacology designed to overcome traditional biological resistance:

• Targeted Monoclonal Antibody: Humanized anti-HER2 IgG1 monoclonal antibody with amino acid sequence identical to trastuzumab, selectively binding to extracellular HER2 domain IV on tumor cell membranes.
• Potent Topoisomerase I Inhibitor Payload: Conjugated with DXd (an exatecan derivative), an inhibitor approximately 10-fold more potent than SN-38 (the active metabolite of irinotecan).
• High Drug-to-Antibody Ratio (DAR 8:1): Carries an optimized drug load of approximately 8 payload molecules per antibody, four times higher than first-generation ADCs (such as T-DM1).
• Tumor-Selective Cleavable Linker & Bystander Effect: The tetrapeptide-based linker is stable in circulation but selectively cleaved by lysosomal cathepsins upregulated inside tumor cells. The released payload is highly cell-membrane permeable, diffusing into neighboring tumor cells to elicit potent "bystander tumor killing" even in heterogeneous, low-HER2-expressing tumor microenvironments.

Pivotal Clinical Trial Milestones

Clinical efficacy has been established in practice-changing global Phase 3 trials:

• DESTINY-Breast03: Demonstrated superior progression-free survival (PFS) and overall survival (OS) compared to standard-of-care trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and a taxane.
• DESTINY-Breast04: Established Enhertu as the first targeted biologic to demonstrate statistically significant, clinically meaningful survival prolongation in patients with HER2-low (IHC 1+ or IHC 2+/ISH-) metastatic breast cancer.
• DESTINY-Gastric & DESTINY-Lung: Significant objective response rates (ORRs) and durable disease control in HER2-positive locally advanced or metastatic gastric cancer and activating HER2-mutant NSCLC.

Infusion Protocol & Safety Monitoring Standards

Administration protocols require strict adherence to clinical safety measures:

• Intravenous Administration: Delivered as an intravenous infusion once every 3 weeks (21-day cycle). The initial infusion is administered over 90 minutes; subsequent infusions can be administered over 30 minutes if well tolerated. Dosing is strictly calculated based on patient weight (5.4 mg/kg for breast and lung indications; 6.4 mg/kg for gastric cancer).
• Interstitial Lung Disease (ILD) / Pneumonitis Surveillance: ILD is a known class toxicity of topoisomerase ADCs. Patients must be proactively monitored for respiratory symptoms (cough, dyspnea, fever). High-resolution chest CT scans and prompt steroid intervention are mandatory for grade ≥1 ILD.
• Left Ventricular Ejection Fraction (LVEF): Baseline and regular echocardiography or MUGA scans are required to ensure cardiac ejection fraction remains within safe limits (>50%).

Global Cold-Chain Sourcing via Critical Kare Pharma

Specialty cancer clinics, hospital pharmacies, and eligible patients worldwide rely on Critical Kare Pharma for compliant cross-border procurement of genuine Enhertu 100mg:

• Compliant Regulatory Clearances: Facilitated under US FDA Personal Importation Policy (PIP), UK MHRA Named-Patient Import, Australian TGA Special Access Scheme (SAS), Brazilian ANVISA RDC import exemptions, and Middle East MOHAP authorizations.
• Uncompromising Cold-Chain (2°C–8°C): Shipped in validated thermal packaging with continuous digital temperature data loggers to ensure biological integrity from dispatch to clinic receipt.
• Full Batch Authentication: Supplied in original tamper-evident manufacturer cartons accompanied by official batch test reports and Certificates of Analysis.

Contact our precision oncology desk for institutional procurement, batch availability, and express international shipping options: support@Critical Kare Pharma.com or connect directly with our oncology pharmacists via WhatsApp (+91 94275 19809).